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Abstract
Background: Non-invasive biochemical markers are
needed to support the diagnosis of ulcerative colitis
(UC), an incurable disease of unknown pathology.
Midkine is an angiogenic cytokine, chemotactic
towards neutrophils and macrophages, and a T-regu-
latory cell suppressor.
Methods: Serum midkine was measured immunoen-
zymatically in 93 UC patients and 108 healthy sub-
jects, and evaluated with respect to disease status,
endoscopic, inflammatory and angiogenic activity.
The diagnostic value of midkine was compared to C-
reactive protein (CRP) using receiver operating char-
acteristics (ROC) analysis.
Results: Midkine was higher (p-0.0001) in inactive
(199 ng/L) and active UC (351 ng/L) compared with
controls (93 ng/L), and reflected disease activity
(rs0.427, p-0.001). Midkine was correlated with CRP,
erythrocyte sedimentation rate (ESR), leukocytes,
platelets, interleukin-6, paraoxonase-1, albumin, trans-
ferrin, iron, hemoglobin, and hematocrit. Midkine cor-
related with angiogenic factors: vascular endothelial
growth factor-A and platelet-derived growth factor-
BB. As a marker of UC, midkine showed a diagnostic
accuracy of 85%, sensitivity of 72%, specificity of 82%,
whereas CRP showed 83%, 65% and 91%, respective-
ly. As a marker of active UC, midkine showed a diag-
nostic accuracy of 87%, sensitivity of 84%, specificity
of 75%, whereas CRP showed 75%, 63% and 83%,
respectively. Combined assessment of midkine and
CRP improved sensitivity but substantially decreased
specificity.
Conclusions: UC is associated with increased circu-
lating midkine, which corresponds with clinical, endo-
scopic, inflammatory and angiogenic activity, and
anemia. Performance of midkine as a marker of UC
or active UC was comparable to that of CRP.
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Introduction
Ulcerative colitis (UC), one of two major phenotypes
of inflammatory bowel disease (IBD), is a chronic,
relapsing inflammatory condition confined to the
colon and rectum. The pathogenesis of IBD is not fully
understood, however, it is presumed that the disease
results from the coexistence of genetic predisposition,
immune disregulation, epithelial barrier dysfunction,
and abnormal microbial composition leading to an
excessive immune response to pathogenic or func-
tionally altered commensal enteric bacteria in suscep-
tible subjects (1, 2).
The diagnosis of IBD presents some difficulties in
clinical practice due to overlapping of symptoms with
non-inflammatory functional bowel disorders (3).
Since recognition of IBD requires extensive, invasive
and expensive investigation, low-cost and non-
invasive biochemical markers facilitating differential
diagnosis are needed (4).
Midkine is a multifunctional, heparin-binding growth
factor, transiently expressed during fetal develop-
ment and subsequently during tissue repair and
remodeling. However, pathological midkine overex-
pression has been also observed and associated with
chronic inflammation, angiogenesis and neoplastic
transformation (5, 6). Its enhanced intestinal expres-
sion has recently been reported in animal models of
UC (7) and in human UC-associated adenocarcinomas
(8). However, whether midkine up-regulation occurs
in human UC and whether is a local pheno-
menon confined to inflamed gut tissue or manifests
itself at systemic level remains unknown.
Thus, we assessed the concentrations of circulating
midkine in patients with UC with respect to disease
activity and the severity of inflammatory response.
We also evaluated midkine as possible marker of UC
in comparison with C-reactive protein (CRP), currently
the only widely used biochemical marker.
Materials and methods
Patients
Ninety-three patients with UC presenting to the Department
of Gastroenterology and Hepatology, Wroclaw Medical
University, Wroclaw, Poland because of disease flare up or
monitoring were enrolled in this study. Patients with coex-
istence of other severe systemic diseases, malignancies,
liver diseases, or pregnancies were not included. Of the
enrolled subjects, 55 presented with inactive and 38 with
active disease. For assessment of disease activity the clinical
activity index (CAI), also known as the Rachmilewitz index
(RI), was used. CAI ranges from 0 to 23 and encompasses
stool frequency, number of stools with blood, general well-
being, abdominal pain/cramp, fever, extraintestinal manifes-
tations, and laboratory tests: erythrocyte sedimentation rate
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Table 1 Characteristics of the study population.
Index Controls Inactive UC Active UC p-Value
Age, years (range) 40.8 (21–66) 47.7 (18–78) 43.3 (18–79) 0.198t
Gender, M/F 44/64 32/23 20/18 0.087x
2
UC duration, years (range) – 7.0 (5.0–10.0) 3.5 (1.5–11.3) 0.303M
Age at onset, years (range) – 40.6 (35.7–45.6) 33.4 (28.2–38.6) 0.048t
Albumin, g/L 48.3 (47.2–49.5) 45.9 (44.7–48.2)a 43.9 (39.4–45.5)a,b -0.0001K
CRP, mg/L 0 (0–1.04) 12.87 (5.05–28.10)a 78.31 (20.95–139.35)a,b -0.0001K
ESR, mm/h 8.7 (4.6–16.2)c 12.3 (9.5–15.8) 28.7 (21.9–37.7)a,b -0.001A
Hb, g/L 138 (128–147)c 135 (127–138) 117 (104–126)a,b 0.0001K
HCT, % 41.6 (38.7–44.5)c 41.0 (39.1–42.0) 35.5 (33.1–38.5)a,b 0.0001K
RBC, =109/L 4.72 (4.31–5.12)c 4.59 (4.45–4.73) 4.18 (3.72–4.51)a,b 0.002K
Iron, mmol/L 18.2 (16.1–20.4) 16.6 (14.4–18.8) 10.9 (8.8–12.9)a,b -0.001A
IL-1, ng/L 0.79 (0–2.42) 0.88 (0.59–1.67) 0.88 (0.34–3.14) 0.538K
IL-6, ng/L 0.68 (0.54–0.76) 1.48 (0.93–2.52)a 4.09 (1.82–6.18)a,b -0.0001K
TNF-a, ng/L 0.62 (0.21–1.59) 0.44 (0.19–1.40) 0.53 (0.21–1.19) 0.979K
PLT, =109/L 241 (197–295)c 274 (253–292) 349 (304–416)a,b -0.001K
TRANSF, g/L 2.85 (2.67–3.03) 2.86 (2.60–3.03) 2.45 (2.16–2.60)a,b -0.001K
WBC, =109/L 5.25 (4.44–6.20)c 6.20 (5.71–7.20) 8.40 (6.64–9.91)a,b 0.008K
Unless otherwise stated, data are presented with 95% CI around mean/median. aSignificantly different from controls; bsigni-
ficantly different from inactive UC; cnot evaluated in blood donors; x
2
Chi-square test; KKruskal-Wallis test; AANOVA; tt-test for
independent samples; MMann-Whitney U-test. UC, ulcerative colitis; M/F, males/females ratio; ESR, erythrocyte sedimentation
rate; Hb, hemoglobin; HCT, hematocrit; RBC, red blood cell count; IL, interleukin; TNF, tumor necrosis factor; PLT, platelet
count; TRANSF, transferrin; WBC, white blood cell count; CRP, C-reactive protein.
(ESR) and hemoglobin (Hb) concentration. Endoscopic find-
ings were evaluated as follows: a score of 0 was allocated
for inactive disease, 1 for mild disease (erythema, decreased
vascular pattern, mild friability), 2 for moderate disease
(marked erythema, lack of vascular pattern, friability, ero-
sions), and 3 for severe disease (spontaneous bleeding,
ulceration). For reference, 108 healthy subjects were recruit-
ed: 39 healthy volunteers from the hospital staff and 69 from
the Regional Center of Blood Donation and Therapy,
Wroclaw, Poland. Detailed characteristics of the study pop-
ulation are presented in Table 1.
Anemia was recognized when Hb concentrations were
below 120 g/L in females and 130 g/L in males.
Analytical methods
Blood samples were collected by venipuncture from fasting
subjects into serum separator tubes and into citrate-tubes.
Serum was obtained from clotted (15 min, room tempera-
ture) and centrifuged (15 min, 720 g) blood. Citrated whole
blood was centrifuged (15 min, 720 g) and plasma was col-
lected. Serum and plasma were stored at –808C until
analysis.
Serum midkine was measured using an enzyme double-
antibody indirect immunoassays with human midkine ELISA
provided by Biovendor (Brno-Modrˇice, Czech Republic)
according to the manufacturer’s instructions. An intra-assay
CV for this assay is 4.5% and inter-assay CV is 6.3%, analy-
tical sensitivity is 33 ng/L.
High-sensitive CRP (HS CRP) was assessed in serum by
the latex particle-enhanced immunoturbidimetric method
with the CRPex-HS CRP test (Good Biotech Corp., Taichung,
Taiwan). Serum transferrin (TRANSF) was determined using
the enhanced immunoturbidimetric method, iron with chro-
mazurol B method, and albumin with the bromocreasol
green method by Stamar (Dabrowa Gornicza, Poland).
Serum interleukins-1 and -6 (IL-1 and -6), and tumor necrosis
factor (TNF)-a were measured using an enzyme double-anti-
body indirect immunoassays with PeliKine Compact human
IL-1, IL-6, and TNF-a ELISA kits, respectively, supplied by
Sanquin (Amsterdam, Netherlands).
Plasma paraoxonase-1 activity (PON1) was determined as
the rate of phenylacetate (ChemService Inc., West Chester,
PA, USA) hydrolysis followed spectrophotometrically as the
increase in absorbance at 270 nm at 258C.
The serum concentration of vascular endothelial growth
factor (VEGF)-A was assayed by an immunoenzymatic meth-
od with tests provided by IBL (Hamburg, Germany). Serum
platelet-derived growth factor (PDGF)-BB was measuredwith
Human PDGF-BB Stratikine ELISA provided by Strathmann
Biotec GmbH (Hamburg, Germany).
Other laboratory indices were assessed with routine auto-
mated procedures.
Statistical analysis
The distribution of data was analyzed with the D’Agostino-
Pearson test. Non-normally distributed data (midkine) are
presented as medians and compared with Mann-Whitney
U-test or Kruskal-Wallis test (multigroup comparisons).
Normally distributed data (either raw or log-transformed) are
presented as means and analyzed with t-test for independent
samples or one-way ANOVA. Means and medians are pre-
sented with 95% confidence intervals (CI). Correlation anal-
ysis was conducted using Spearman’s rank correlation test.
Second order correlation coefficients were calculated in
order to obtain the net correlation for four interrelated
variables. Frequency analysis was conducted with the x2-
test. All calculated p-values were two-sided and pF0.05 was
considered statistically significant.
The diagnostic value of midkine and CRP was evaluated
using receiver operating characteristics (ROC) curve analy-
sis. The overall performance was expressed as the area
under the ROC curve (AUC) with 95% CI and p-statistics for
the difference between calculated AUC and AUCs0.5 (mark-
er without discriminative power). A cut-off value correspond-
ing to the highest accuracy was determined and the related
sensitivities and specificities as well as likelihood ratios for
positive and negative results were calculated. In the evalu-
ation of combined midkine and CRP assessment, the rule ‘‘at
least 1 of the 2 markers positive’’ was applied as the criterion
for test positivity.
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Table 2 Relationship between disease activity, inflammatory response and circulating midkine in patients with ulcerative
colitis compared with CRP and ESR.
Variables Midkine CRP ESR
CAI rs0.427, p-0.001 rs0.360, ps0.007 rs0.497, ps0.0001
Endoscopy rs0.266, ps0.016 rs0.422, p-0.001 rs0.498, p-0.0001
CRP rs0.326, ps0.004 – rs0.527, p-0.0001
ESR rs0.401, p-0.001 – –
WBC rs0.365, p-0.001 rs0.399, p-0.001 rs0.406, ps0.0001
PLT rs0.394, p-0.001 rs0.286, ps0.012 rs0.564, p-0.0001
IL-1 rs0.024, ps0.849 rs0.115, ps0.397 rs–0.010, ps0.935
IL-6 rs0.350, ps0.006 rs0.527, ps0.0001 rs0.578, p-0.0001
TNF-a rs–0.046, ps0.713 rs0.080, ps0.553 rs0.004, ps0.976
PON1 rs–0.473, ps0.0001 rs–0.413, ps0.002 rs–0.362, ps0.004
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; CAI, clinical activity index (Rachmilewitz Index); WBC, white
blood cell count; PLT, platelet count; IL, interleukin; TNF, tumor necrosis factor; PON1, paraoxonase 1.
Figure 1 Serum midkine concentrations in patients with
inactive and active ulcerative colitis (UC) compared to
healthy subjects.
Median midkine concentrations are shown with 95% confi-
dence intervals.
The entire statistical analysis was conducted with Med-
Calc Version 10.1.0.0 software (Mariakerke, Belgium) with
the exception of partial correlation analysis for which
VassarStats was applied (available from http://faculty.vassar.
edu/lowry/VassarStats.html).
Ethical considerations
The study protocol was approved by the medical Ethics
Committee of our University and was in accordance with the
ethical standards formulated in the Helsinki Declaration of
1975. Informed consent was obtained from all subjects.
Results
Circulating midkine in UC
Midkine concentrations in patients with both active
and quiescent UC were significantly increased com-
pared to healthy subjects (Figure 1). Midkine correlat-
ed directly with disease clinical activity and, although
weakly, with endoscopy findings (Table 2).
Midkine also correlated directly with CRP, ESR,
white blood cell count (WBC), and platelet count
(PLT). It correlated indirectly with negative acute-
phase response proteins – albumin and TRANSF. Of
the proinflammatory cytokines, midkine, similarly to
CRP and ESR, correlated with IL-6, but not with TNF-
a and IL-1. A negative correlation with the activity of
PON1 was also observed (Tables 2 and 3).
Since midkine, disease activity, ESR and CRP were
all interrelated, we calculated the second order partial
correlation coefficients to obtain the netto correlation
between factors. These were as follows: for midkine
and disease activity rs0.272, ps0.009, for midkine
and CRP rs0.115, ps0.278, for midkine and ESR
rs0.173, ps0.101. Partial correlation coefficients for
midkine and endoscopy findings, following the
removal of the effects of CRP and ESR, were rs0.054,
ps0.611.
Midkine concentrations were significantly higher in
anemic patients with UC compared with those with-
out anemia w377 ng/L (95% CI: 288–565) vs. 202 ng/L
(169–260), ps0.0001x. Midkine was negatively corre-
lated with Hb and iron concentrations and with
hematocrit (HCT) (Table 3). Patients who reported
substantial involuntary weight loss had insignificantly
higher midkine concentrations compared with those
who did not w294 ng/L (189–798) vs. 256 ng/L
(183–431), ps0.397x.
Midkine concentrations correlated directly with
concentrations of angiogenic factors – VEGF-A and
PDGF-BB (Table 3).
No significant correlation was found between
midkine concentrations and patient age (rs–0.128,
ps0.222), age at onset of disease (rs–0.073, ps
0.520) or disease duration (rs–0.207, ps0.060). There
was no significant differences (ps0.401) in cytokine
concentrations between female w294 ng/L (219–382)x
and male w242 ng/L (185–297)x participants.
Midkine as a possible disease marker in UC
Midkine as a marker of the presence of UC (both
active and inactive) had an AUCs0.848 (0.791–0.895),
ps0.0001. Using 178 ng/L as a cut-off value, the mark-
er showed a sensitivity of 72% and specificity of 82%.
The likelihood ratio for a positive result was 3.89, and
the likelihood ratio for a negative result was 0.34. CRP
had an AUCs0.830 (0.760–0.886), ps0.0001. Using
10.4 mg/L as a cut-off value, CRP had a sensitivity of
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Table 3 Relationship between nutritional indices, hematological parameters, angiogenic factors and circulating midkine in
patients with ulcerative colitis compared with CRP and ESR.
Variables Midkine CRP ESR
Albumin rs–0.368, p-0.001 rs–0.411, p-0.001 rs–0.362, p-0.001
TRANSF rs–0.295, ps0.007 rs–0.296, ps0.013 rs–0.288, ps0.010
Iron rs–0.312, ps0.005 rs–0.601, p-0.0001 rs–0.409, p-0.001
Hb rs–0.363, p-0.001 rs–0.365, ps0.001 rs–0.470, p-0.0001
HCT rs–0.357, p-0.001 rs–0.353, ps0.002 rs–0.483, p-0.0001
RBC rs–0.175, ps0.099 rs–0.180, ps0.114 rs–0.257, ps0.016
MCV rs–0.275, ps0.009 rs–0.262, ps0.022 rs–0.328, ps0.002
PDGF–BB rs0.359, ps0.006 rs0.127, ps0.374 rs0.277, ps0.036
VEGF-A rs0.402, ps0.008 rs–0.053, ps0.837 rs0.190, ps0.462
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TRANSF, transferrin; Hb, hemoglobin; HCT, hematocrit; RBC,
red blood cell count; MCV, mean corpuscular volume; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth
factor.
65% and specificity of 91%. The likelihood ratio for a
positive result was 6.92, and 0.38 for a negative result.
Combining both markers increased test sensitivity to
91% but decreased specificity to 70%. Corresponding
likelihood ratios were 3.0 and 0.13 for positive and
negative test results, respectively.
Midkine as a marker for patients with active UC had
an AUCs0.870 (0.816–0.913), ps0.0001. Using a cut-
off value of 202 ng/L, midkine had a sensitivity of 84%
and specificity of 75%. The likelihood ratio for a pos-
itive result was 3.35, and 0.21 for a negative result.
CRP had an AUCs0.751 (0.674–0.817), ps0.0001.
Using a cut-off value of 10.4 mg/L, CRP had a sensi-
tivity of 63% and specificity of 83%. The likelihood
ratio for a positive result was 3.60 and 0.45 for a nega-
tive result. Combining both markers increased test
sensitivity to 87% but decreased specificity to 47%.
Corresponding likelihood ratios were 1.65 and 0.28 for
positive and negative test results, respectively.
Discussion
The up-regulation of midkine expression has been
observed frequently in a number of pathological con-
ditions (9). At the systemic level, however, increases
in midkine have been reported almost exclusively in
cancer (10, 11). To date, rheumatoid arthritis repre-
sents the only inflammatory disease in which an
increase in circulating midkine concentrations has
been observed (12). Thus, our paper supports the link
between midkine and inflammation at the systemic
level.
Tokuyama et al. (8) demonstrated increased mid-
kine expression in colon adenocarcinoma, which
increased along with tumor progression. Midkine has
been overexpressed in sporadic and to a lesser
degree, UC-associated tumors. These authors report-
ed increased concentrations of midkine in UC-regen-
erative mucosa. This finding implies midkine
involvement not only in UC-associated neoplastic
transformation, but also in the healing process of UC.
The latter finding corroborates the observations of
Yuki et al. (7), who demonstrated midkine overex-
pression in a rat model of disease and suggested its
involvement in reepithelialization and modulation of
the cell-matrix interactions during the process of gut
repair. Midkine contributions to the healing process
in UC is further supported by its participation in the
healing of gastric deep ulcers (13).
Our study shows up-regulation of midkine in UC at
the systemic level. Midkine expression has been
found in epithelial cells of intestinal mucosa and
endothelial cells of gut blood vessels (8). Also,
immune cells infiltrating inflamed tissue (14), such
as lymphocytes (15), neutrophiles (16), and macro-
phages (17), may contribute to increased concen-
tration of midkine. Platelets, which can selectively
scavenge angiogenic factors and release them upon
activation (18), may be another possible source of this
cytokine. Accordingly, we observed increased PLTs in
active UC, as well as direct correlation between mid-
kine and platelet or leukocyte counts.
We demonstrated that midkine was slightly in-
creased in patients in remission, which is in agree-
ment with its suggested role in gut healing. However,
midkine elevations were associated primarily with
flare up of disease and correlated directly with dis-
ease activity indices, which may imply its involve-
ment in the pathogenesis of UC. The association with
disease activity was valid for its clinical rather than
endoscopic evaluation, as revealed by the removal of
the effects exerted by CRP and ESR. Concerning the
inclusion of Hb in the CAI, the association of midkine
with hematological variables, consistent with our pre-
vious studies (19, 20), may account for the relation-
ship of midkine with clinical activity of UC.
Midkine moderately reflected the systemic inflam-
matory response, being correlated with immune cell
counts, acute-phase proteins and cytokines/growth
factors with proinflammatory properties. However,
except for PON1, the observed associations were
weaker than those of CRP and ESR, the inflammatory
indices of clinical relevance in UC (4). Similar to
Crohn’s disease (CD) (20) and gastrointestinal tract
cancers (21), midkine increases in UC correlated with
a drop in the activity of PON1. This enzyme plays a
role in the gastrointestinal tract as a local detoxifier,
antioxidant, immunomodulator, and/or quorum-
quenching factor (22). Our results are in agreement
with postulated involvement of midkine in the per-
petuation and exacerbation of the inflammatory
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response (5, 6). It may play a role in recruitment of
neutrophils and macrophages into inflamed tissue
(23, 24), and up-regulation of synthesis of inflamma-
tory mediators (25–27). Animal studies have revealed
that several inflammation-related phenomena were
substantially alleviated in midkine-deficient animals
(12, 25, 28–32). The mechanisms mentioned above
may also operate in the involvement of midkine in the
pathogenesis of UC since the accumulation of neutro-
philes and monocytes associated with aberrant
inflammatory response is essential for development
of UC (14). Recently, midkine was found to act as a
suppressor of T regulatory lymphocytes (Treg) (31),
the dysfunction of which contributes to immune
abnormalities of mucosa (33, 34). Wang et al. (31)
demonstrated that attenuated symptoms of enceph-
alomyelitis in midkine-deficient animals resulted from
increased Treg cell population. Midkine was found to
decrease cell number in a dose-dependent manner,
whereas the administration of anti-midkine RNA apta-
mers expanded the Treg cell population.
Furthermore, although immune-driven angiogene-
sis seems to be a secondary event to abnormal
immune response/barrier dysfunction in the patho-
genesis of IBD, it substantially contributes to the
chronic character of the disease (34). Several of the
properties of midkine support angiogenesis – it
exhibits mitogenic, differentiation, and chemotactic
activity towards vascular endothelial and smooth
muscle cells (26, 29, 35) and facilitates remodeling of
extracellular matrix (36). Also, the recruitment of
inflammatory cells secreting angiogenic factors indi-
rectly supports angiogenesis (37). Accordingly, in the
present study midkine increases corresponded with
increasing concentrations of VEGF-A and PDGF-BB,
the prominent angiogenic factors involved in the
pathogenesis of IBD (38).
The need for biochemical markers facilitating clini-
cal decision-making has recently been stressed (4).
Especially non-invasive and economical markers for
supporting the differential diagnosis of UC from
subjects with non-inflammatory functional bowel
disorders are needed. Therefore, apart from ability of
midkine to detect UC, we evaluated the ability to dis-
tinguish patients with active UC from healthy subjects
and patients with quiescent disease, the latter group
being a surrogate for subjects with non-inflammatory
bowel disorders. The overall performance of midkine
as a marker for UC was similar to that of CRP. Midkine
proved to be a more sensitive, while CRP proved to
be a more specific indicator of UC. However, the like-
lihood ratio for a positive result obtained with CRP
was twice that of midkine, demonstrating that CRP is
superior in ruling in disease. More substantial differ-
ences in midkine and CRP performance were
observed in distinguishing active disease – midkine
accuracy was considerably greater than that of CRP.
Again, midkine proved to be a more sensitive, while
CRP proved to be a more specific marker. Simulta-
neous measurement of both factors resulted in insig-
nificant improvement in sensitivity and considerable
worsening of specificity. The fact that midkine per-
formance as a marker for UC was not substantially
better than that for CRP implies its limited usefulness
for clinical application in case of this disease. Our
results obtained for midkine as a disease marker in
CD (20), superior to those obtained for UC, imply that
midkine better reflects inflammation in CD than in UC.
Correspondingly, CD has been found to be associated
with a greater CRP response than in UC (39). This may
reflect different pathophysiology involved in the
development of both diseases.
Taking into account the findings of Tokuyama et al.
(8) on enhanced expression of midkine in UC-associ-
ated dysplasia, it cannot be excluded that midkine
increases in some patients with clinically and endo-
scopically inactive disease may reflect UC-associated
neoplastic transformation. Presently, there is no other
instrument for oncologic surveillance of UC patients
other than invasive and expensive endoscopy asso-
ciated with histopathological examination of biopsy
specimen. In this respect, the possible use of midkine
as an early cancer marker for surveillance of UC
patients is intriguing and warrants further investi-
gations.
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